أستونيا - الإستونية - Ravimiamet

alfasan nederland b.v. - levometadoon+fenpipramiid - süstelahus - 5mg+0,25mg 1ml 50ml 1tk; 5mg+0,25mg 1ml 5ml 1tk

أستونيا - الإستونية - Ravimiamet

kalceks as - naatriumoksübaat - suukaudne lahus - 500mg 1ml 180ml 1tk

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - kartsinoom, mitteväikerakk-kopsu - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

bioprojet pharma - pitolisant - sleep apnea, obstructive - muud närvisüsteemi ravimid - ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa).

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

pfizer europe ma eeig  - palbociclib - rinnanäärmed - antineoplastilised ained - ibrance on näidustatud ravi hormooni retseptori (hr) positiivne, inimese epidermaalse kasvufaktori retseptor 2 (her2) negatiivne lokaalselt kaugelearenenud või metastaatilise rinnavähi:kombinatsioonis aromataasi inhibiitor;koos fulvestrant naistel, kes on saanud enne endokriinse ravi. pre - või perimenopausal naised, endokriinse ravi tuleks koos luteiniseeriva hormooni vabastav hormoon (lhrh) agonist.

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - leukeemia, lümfotsüütne, krooniline, b-rakk - antineoplastilised ained - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

أستونيا - الإستونية - Ravimiamet

accord healthcare b.v. - kodeiin+paratsetamool - tablett - 30mg+500mg 50tk; 30mg+500mg 16tk; 30mg+500mg 20tk

أستونيا - الإستونية - Ravimiamet

actavis group ptc ehf. - paratsetamool+kodeiin - tablett - 500mg+8mg 20tk

أستونيا - الإستونية - Ravimiamet

ennogen healthcare (europe) limited - dihüdrokodeiin - toimeainet prolongeeritult vabastav tablett - 60mg 10tk; 60mg 56tk

أستونيا - الإستونية - Ravimiamet

vitabalans oy - kodeiin+paratsetamool - tablett - 30mg+500mg 10tk; 30mg+500mg 30tk; 30mg+500mg 100tk